RxDoctor Payments Data

Jing-Sheng Zheng, MD

Cardiovascular Disease · Galloway, NJNPI 1992784565

Payments from drug & device makers

$30,433in general payments, 2019–2025

Across 611 payments — averaging $49.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Siemens Medical Solutions USA, Inc.$13K
  • Abbott$4K
  • Boston Scientific$2K
  • AstraZeneca$2K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Medtronic$1K
  • plus $7K from 34 others

What the payments were for

  • Speaking & faculty fees$4,00013%
  • Travel & lodging$13,75045%
  • Food & beverage$12,66242%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,433 in reported general payments places this provider in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$336,608
Medicare patients
990
Services billed
2,852

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten22$180,986
EliquisApixaban96$128,010
FarxigaDapagliflozin Propanediol70$95,163
EntrestoSacubitril/Valsartan42$54,167
XareltoRivaroxaban18$26,789
VerquvoVericiguat16$16,359
Praluent PenAlirocumab11$12,332
Atorvastatin Calcium306$4,493
Losartan Potassium311$3,902
Ranolazine ErRanolazine41$3,060
Carvedilol283$2,732
Rosuvastatin Calcium121$2,671
Ezetimibe60$2,431
Hydralazine Hcl107$2,239
Diltiazem 24hr Er (Cd)Diltiazem Hcl81$2,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$1,167$180,98622 claims
PfizerEliquis$987$128,01096 claims
AstraZenecaFarxiga$1,559$95,16370 claims
NovartisEntresto$731$54,16742 claims
Johnson & JohnsonXarelto$1,036$26,78918 claims
MerckVerquvo$505$16,35916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Galloway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →